179 related articles for article (PubMed ID: 24674234)
1. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.
Vagenas P; Di Paola A; Herme M; Lincoln T; Skiest DJ; Altice FL; Springer SA
J Subst Abuse Treat; 2014 Jul; 47(1):35-40. PubMed ID: 24674234
[TBL] [Abstract][Full Text] [Related]
2. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.
Mitchell MC; Memisoglu A; Silverman BL
J Stud Alcohol Drugs; 2012 Nov; 73(6):991-7. PubMed ID: 23036218
[TBL] [Abstract][Full Text] [Related]
3. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
[TBL] [Abstract][Full Text] [Related]
4. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
Springer SA; Di Paola A; Azar MM; Barbour R; Biondi BE; Desabrais M; Lincoln T; Skiest DJ; Altice FL
J Acquir Immune Defic Syndr; 2018 May; 78(1):43-53. PubMed ID: 29373393
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
Korthuis PT; Lum PJ; Vergara-Rodriguez P; Ahamad K; Wood E; Kunkel LE; Oden NL; Lindblad R; Sorensen JL; Arenas V; Ha D; Mandler RN; McCarty D;
Addiction; 2017 Jun; 112(6):1036-1044. PubMed ID: 28061017
[TBL] [Abstract][Full Text] [Related]
6. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.
Springer SA; Di Paola A; Barbour R; Azar MM; Altice FL
J Acquir Immune Defic Syndr; 2018 Sep; 79(1):92-100. PubMed ID: 29781884
[TBL] [Abstract][Full Text] [Related]
7. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.
Springer SA; Altice FL; Herme M; Di Paola A
Contemp Clin Trials; 2014 Mar; 37(2):209-18. PubMed ID: 24384538
[TBL] [Abstract][Full Text] [Related]
8. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.
Pettinati HM; Gastfriend DR; Dong Q; Kranzler HR; O'Malley SS
Alcohol Clin Exp Res; 2009 Feb; 33(2):350-6. PubMed ID: 19053979
[TBL] [Abstract][Full Text] [Related]
9. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
10. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.
Tetrault JM; Tate JP; McGinnis KA; Goulet JL; Sullivan LE; Bryant K; Justice AC; Fiellin DA;
Alcohol Clin Exp Res; 2012 Feb; 36(2):318-24. PubMed ID: 21797892
[TBL] [Abstract][Full Text] [Related]
11. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
12. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Malone M; McDonald R; Vittitow A; Chen J; Obi R; Schatz D; Tofighi B; Garment A; Kermack A; Goldfeld K; Gold H; Laska E; Rotrosen J; Lee JD
Contemp Clin Trials; 2019 Jun; 81():102-109. PubMed ID: 30986535
[TBL] [Abstract][Full Text] [Related]
13. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
Hartung DM; McCarty D; Fu R; Wiest K; Chalk M; Gastfriend DR
J Subst Abuse Treat; 2014 Aug; 47(2):113-21. PubMed ID: 24854219
[TBL] [Abstract][Full Text] [Related]
14. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.
Springer SA; Di Paola A; Azar MM; Barbour R; Krishnan A; Altice FL
Drug Alcohol Depend; 2017 May; 174():158-170. PubMed ID: 28334661
[TBL] [Abstract][Full Text] [Related]
15. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
Syed YY; Keating GM
CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
[TBL] [Abstract][Full Text] [Related]
16. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
Nunes EV; Krupitsky E; Ling W; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
J Addict Med; 2015; 9(3):238-43. PubMed ID: 25901451
[TBL] [Abstract][Full Text] [Related]
17. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
Lucey MR; Silverman BL; Illeperuma A; O'Brien CP
Alcohol Clin Exp Res; 2008 Mar; 32(3):498-504. PubMed ID: 18241321
[TBL] [Abstract][Full Text] [Related]
18. Extended-release naltrexone and harm reduction counseling for chronically homeless people with alcohol dependence.
Collins SE; Duncan MH; Smart BF; Saxon AJ; Malone DK; Jackson TR; Ries RK
Subst Abus; 2015; 36(1):21-33. PubMed ID: 24779575
[TBL] [Abstract][Full Text] [Related]
19. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
[TBL] [Abstract][Full Text] [Related]
20. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
